Aurobindo Pharma surges as its arm obtains marketing authorization from MHRA for Dyrupeg
Aurobindo Pharma is currently trading at Rs. 1118.55, up by 14.55 points or 1.32% from its previous closing of Rs. 1104.00 on the BSE.
The scrip opened at Rs. 1119.90 and has touched a high and low of Rs. 1119.90 and Rs. 1114.00 respectively. So far 4888 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1592.55 on 13-Sep-2024 and a 52 week low of Rs. 994.35 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1119.90 and Rs. 1079.05 respectively. The current market cap of the company is Rs. 64829.08 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.56% and 6.61% respectively.
Aurobindo Pharma’s wholly owned step-down subsidiary -- CuraTeQ Biologics s.r.o. has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, its pegylated filgrastim biosimilar version. Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ’s third biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
